Ribonucleotide Transfer RNA: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: RPTN

NCBI ID: G126638

RPTN

Other Name(s): RPTN_HUMAN | Repetin | intermediate filament-associated protein | repetin

Ribonucleotide Transfer RNA: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Ribonucleotide transfer RNA (RPTN) is a protein that plays a crucial role in the process of gene expression and translation of RNA into protein. Mutations in the RPTN gene have been linked to a range of human diseases, including cancer, neurodegenerative diseases, and genetic disorders. As a result, RPTN has emerged as a promising drug target for the development of new treatments for these diseases. In this article, we will explore the biology of RPTN and its potential as a drug target.

The RPTN gene

Ribonucleotide transfer RNA (RPTN) is a small non-coding RNA molecule that plays a central role in the process of gene expression and translation of RNA into protein. The RPTN gene is located on chromosome 19 and consists of approximately 1,300 amino acid residues. RPTN gene is expressed in most tissues and cells of the body, including the brain, heart, and blood cells.

The function of RPTN

RPTN is a key regulator of gene expression and translation of RNA into protein. It functions as a template for the production of RNA by ribosome-directed transcription (RDT) in the cytoplasm of the cell. RPTN uses a specific consensus sequence at its C- terminus to recruit a core RNA binding protein (CBP) to the RNA polymerase II complex. Once the CBP is recruited, it interacts with the RPTN protein and enhances the affinity of the RNA for the RNA polymerase. This interaction between RPTN and CBP allows RPTN to efficiently transcribe RNA into protein.

In addition to its role in gene expression, RPTN is also involved in the regulation of translation of RNA into protein. It has been shown that RPTN can interact with the protein chaperone APPBP (A chaperone-induced transcription-binding protein), which is a protein that can interact with RPTN and enhance its affinity for the ribosome. This interaction between RPTN and APPBP allows RPTN to stabilize the translation complex and enhance the rate of protein synthesis.

Mutations in the RPTN gene

Mutations in the RPTN gene have been linked to a range of human diseases, including cancer, neurodegenerative diseases, and genetic disorders. The most well-known of these mutations is the missense mutation R202G, which is located in the middle of the RPTN gene. This mutation has been shown to cause a gain of function in the RPTN protein and to contribute to the development of neurodegenerative diseases.

Another well-known mutation is the double mutation R204D, which is located at the beginning of the RPTN gene. This mutation has been shown to cause a decrease in the activity of the RPTN protein and to contribute to the development of genetic disorders.

The therapeutic potential uses of RPTN

The therapeutic potential uses of RPTN are vast and varied. As a drug target, RPTN has the potential to be used to treat a range of diseases that are caused by mutations in the RPTN gene, including cancer, neurodegenerative diseases, and genetic disorders.

One of the most promising therapeutic uses of RPTN is its potential as a cancer therapeutic. Many studies have shown that RPTN mutations are associated with the development of cancer. In addition, research has also shown that targeting RPTN with small molecules can be an effective way to inhibit the growth of cancer cells.

Another potential therapeutic use of RPT

Protein Name: Repetin

Functions: Involved in the cornified cell envelope formation. Multifunctional epidermal matrix protein. Reversibly binds calcium

The "RPTN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPTN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets